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Benign prostatic hyperplasia (BPH) is a common urological
condition, and yet there are many puzzles waiting to be
solved. This perspective is to help explain some of these
puzzles, based on our recent publications and previous
clinical studies on BPH.
2. Why small prostates obstruct and some big
prostates do not obstruct?
Clinical BPH as a disease has been defined as benign pros-
tatic enlargement (BPE) [1,2]; however in clinical practice
we still see many patients with no enlargement, with
prostate volume less than 20 g still causing symptoms and
obstruction [3]. How can this be explained?
To solve the puzzle, we first need to redefine clinical BPH.
We need to go back to the basic fundamental pathology
of BPH, which on histology is described as nodular hyper-
plasia [4], not diffused hyperplasia of the whole gland. The
nodular hyperplasia forms nodule (adenoma) or more often
multiple nodules or adenomata (PA). The PA affects mainly
the transitional zone and the periurethral zone of the
prostate. The transitional zone PA gives rise to the lateral
lobes while those in the periurethral zone give rise to the
middle lobe. As the prostate gland is situated around the
bladder neck, the PA would cause a varying degree of
obstruction, depending on the site of the PA. The lateralE-mail address: foo.keong.tatt@singhealth.com.sg.
Peer review under responsibility of Shanghai Medical Associa-
tion and SMMU.
http://dx.doi.org/10.1016/j.ajur.2015.11.003
2214-3882/ª 2016 Editorial Office of Asian Journal of Urology. Producti
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-lobes PA would cause compression of the prostatic urethra
while the middle lobe would distort the funneling effect of
the normal urethral vesical angle, and cause more severe
obstruction. This can be explained by flow dynamics, that
distortion causes more severe obstruction than compres-
sion. As in the example of using the garden hose, bending
the hose (distortion) would stop the flow more effectively
than trying to compress it.
The degree of obstruction also depends on whether the PA
is situated below the sub mucosal layer, or deeper in the
stromaof theprostate.PA in the submucosal layer, evenwhen
small, would cause obstruction early, while the PA in the
stroma would need to grow to a bigger size to cause obstruc-
tion. This would explain why PA can cause obstruction even
when small, and may not cause obstruction even when big.
3. The subcervical adenoma in patients with a
small prostate
This is typically seen in younger patients in the late forties
or early fifties with a history of poor flow and other lower
urinary tract symptoms (LUTS). The PA elevates the bladder
neck high and causes obstruction. This condition is still
called a high bladder neck in the literature, but with better
understanding of the BPH pathology, it is more often due to
the PA siting below the bladder neck, and is not a primary
bladder neck problem [5].
4. Classical median lobe
If the PA arising from the periurethral zone grows into the
bladder, this would give rise to the classical median lobe,on and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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be small without PA, or may also have PA, giving rise to
trilobular obstruction.
Our recent study confirms that of 73 patients with PA, 39
had lateral lobes obstruction, 12 middle lobes and 22 had
trilobular obstruction, and the average flow rate was
16.0 mL/s, 11.9 mL/s and 8.9 mL/s respectively [5].
The above would substantiate our definition of clinical
BPH that clinical BPH is an adenoma or adenomata (PA),
irrespective of size, and it causes a varying degree of
obstruction.
5. What is the relationship between clinical
BPH and LUTS?
Can we treat LUTS/BPH by the symptoms score alone as in
many clinical guidelines? Why do we need to treat clinical
BPH?
Clinical BPH (PA) is a slow progressive disease that
causes obstruction and may eventually cause dysfunctions
of the bladder and kidneys, therefore the need to treat
when the functions of the bladder are threatened. If not,
the condition can still be watched.
The other reason for treatment would be to relieve
bothersome symptoms. Whether the symptoms bother the
patient and whether the patient wants treatment would be
his choice. He needs to know the effectiveness of the
treatment and its side effects to make an informed decision.
Many studies have shown that there is a poor correlation
between the International Prostate Symptoms Score (IPSS)
and obstruction by PA. In a study done by Rosier et al. [6],
of 717 patients studied, 55 patients had a mild symptoms
score of IPSS 0e7, 49% of these patients were not
obstructed and 51% were still obstructed.
In our own study on 79 patients with acute retention of
urine, 36.5% had only mild symptoms before the acute
episode. Of the initial 150 patients, 6.7% had hydro-
nephrosis due to chronic retention [7]. In another study by
Chia et al. [8] of 200 patients with pressure flow studies
(PFS) done, 57% of patients with severe IPSS of 21 or more
were obstructed, but 43% of them were not obstructed.
Thus patients with PA can have severe obstruction with
minimum or no symptoms. While many of those with severe
IPSS may not be obstructed.
Therefore, BPH can further be defined as prostate ade-
noma, causing a varying degree of obstruction, with or
without LUTS [5].
BPH should not be treated by the severity of IPSS alone,
as that would lead to over treatment and under treatment
with regard to obstruction.
6. Classifying severity of BPH (PA)
BPH should be treated by considering both the symptoms
and obstruction. Obstruction would be significant if it
causes the dysfunctions of the bladder, that of storage and
voiding. If the voiding function is affected, there will be
persistent post void residue urine, with 100 mL used as a
cut-off. If there is a storage problem, the patient will have
urinary frequency and low maximum voided volume, lessthan 100 mL. The bothersome symptoms index (quality of
life, QoL) is more important than the IPSS in symptoms
assessment, with a QoL  3 considered bothersome. Thus
the severity of clinical BPH can be classified according to
the stage of the disease [9] and this has been shown to be
feasible [10].
Stage I: patient with no bothersome symptoms and no
significant obstruction;
Stage II: patient with bothersome symptoms but no sig-
nificant obstruction;
Stage III: patient with significant obstruction with or
without bothersome symptoms;
Stage IV: patient with complications of BPH such as
retention of urine, persistent macro haematuria, stones
and UTI.
Going back to basic good clinical practice, treatment
should be decided according to the severity of the disease.
Thus stage I patients can be managed conservatively with
reassurance, fluid adjustment and exercise. Stage II pa-
tients may need medication with alpha blockers, and for
those with large prostates more than 30 g, 5 Alpha Reduc-
tase Inhibitors (5 ARI’s). For stage III patients, surgery
would be an option. Treatment with 5 ARI’s or in combi-
nation with alpha-blockers could be initiated and the pa-
tients followed up closely. Stage IV patients would
generally require surgery [11].
From our experience with 408 patients assessed with the
above, we have shown that staging is useful in managing
patients with LUTS and BPH [12].
However, the diagnosis has to be confirmed before
treatment, especially surgical intervention.7. Diagnosis of clinical BPH (PA)
Diagnosis of PA can be done confidently with non-invasive
transabdominal ultrasound in the clinic, looking for the
intravesical prostatic protrusion (IPP) in the sagittal view.
IPP is the distance in mm from the inner most tip of the
protrusion to the base of the prostate, at the circumfer-
ence of the bladder [13].
The IPP is 100% specific and has 100% positive predictive
value for diagnosing PA in our study [5]. But its negative
predictive value is low at 36%.
The urinary flow rate would help to further differentiate
PA from other causes of LUTS. A diagnosis of no PA or
normal prostate can be made clinically for patients with no
IPP and a good flow rate greater than 20 mL/s [14]. Poor
flow in patients with no IPP can be due to PA in the prostatic
urethra or detrusor underactivity, and a urodynamics study
or flexible cystoscopy would have to be done to determine
the cause.
On the other hand, patients with good flow can still have
PA. In our recent study of patients with a good flow rate of
more than 12.5 mL/s, 65% of patients with grade 3 IPP were
still obstructed based on PFS [15].
With the above understanding, male LUTS can be
differentiated into those with PA and those without, and
they can then be managed separately.
8 K.T. Foo8. PSA does not increase with age
If a patient has no PA, no prostate cancer and no prostatitis,
his prostate specific antigen (PSA) should be less than 1 mg/L,
and the value does not increase with age.
A normal prostate PSA is less than 1 mg/L. This is sug-
gested in our study of patients with PA with varying pre-
operative PSA. Postoperatively, after the enucleation pro-
cedure with total removal of the adenoma, the PSA is
generally less than 1 mg/L [16]. Also, we have patients in
the clinics with LUTS but no PA as defined, and their PSA
does not increase with age on long term follow up, some up
to 15e20 years (unpublished data).
Why should PSA increase with age in the normal
prostate?
Previous studies suggesting that PSA increased with age
is due probably to the original cohort of subjects with no
prostate cancer, but many of them would have a varying
degree of BPH (PA), thus causing the PSA to be higher than
1 mg/L. As the PA progresses with age, the PSA would
appear to increase with age.
For persons with a normal prostate, prostate volume less
than 20 g, no IPP and good flow, the PSA remains the same
over the years and does not increase with age.
9. Grading of IPP
The IPP can be graded according to the degree of protru-
sion, with grade 1: 5 mm; grade 2: 6e10 mm and grade 3:
>10 mm.
The grade of IPP is strongly correlated to the urodynamic
evidence of obstruction. For patients with grade 1 IPP, 21%
are obstructed, whereas for patients with grade 3 IPP, 96%
are obstructed [8].
This would explain why IPP can predict the failure rate
of trial off catheter in patients with acute retention of
urine, with 36% failure rate for grade 1 and 67% failure rate
for grade 3 IPP [13]. IPP can also be used to predict the
progression of clinical BPH. In our study of patients with a
mean follow-up of 32 months, 6% of patients with grade 1
IPP and 44% of grade 3 IPP would deteriorate in terms of
worsening symptoms, developing PVR and requiring surgery
[17]. Our study also showed that IPP is a better predictor of
obstruction (on PFS), than PSA and prostate volume, with
area under the curve (AUC) of 0.77 vs. 0.70 vs. 0.63,
respectively [18].
In our study of 408 patients, 31% of patients had grade
3 IPP and the majority 69% had grade 1 and 2 IPP. This
would explain why the majority of patients with LUTS/
BPH do not deteriorate [12]. In one study of 105 patients
with prostatism presumably due to BPH, only 16% deteri-
orated, of which 9% required surgery after 5 years of
follow-up. Eighty-four percents remained the same or
better [19].
Patients with persistently high residual urine more than
100 mL and high grade prostate would require surgery [11].
Using the staging and grading system for BPH, 9% of pa-
tients in that study required transurethral resection of the
prostate (TURP), 32% were treated medically and 59% were
advised conservative management with fluid adjustment
and lifestyle changes [12]. This conformed closely with thenatural history of BPH, suggesting that patients were not
over treated or undertreated.
10. Conclusion
With the redefinition of BPH, that it is essentially an ade-
noma or multiple adenomata, many of the puzzles of BPH
can be solved and explained. Why some small prostate
obstruct even when small, and big prostates do not obstruct
is dependent on the location of the PA. Patients with LUTS
can be differentiated by whether they have PA or no PA
with non invasive transabdominal ultrasound and uro-
flowmetry. Cost effective treatment can then be individu-
alized, according to the grade and stage of the disease.
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